) recently inked a deal to acquire all shares of Germany-based
Steigerwald Arzneimittelwerk GmbH. Steigerwald Arzneimittelwerk
is a private pharmaceutical company which specializes in
pharmacy-only herbal medicines.
The transaction is expected to close early July this year on
the fulfilment of certain conditions, including antitrust
clearance. The companies kept the financial details of the
transaction undisclosed. Bayer also agreed to take over all
employees (approx. 180 people) of Steigerwald
With the acquisition, Bayer will add Iberogast and Laif in its
product portfolio. While Iberogast is approved for the treatment
of functional gastrointestinal disorders, Laif is approved for
the treatment of mild-to-moderate depression. In 2012,
Steigerwald Arzneimittelwerk recorded sales of €61.3 million.
Bayer has been pretty active on the acquisition front in the
last few months. The company was in the news recently with the
announcement of its intention to acquire
), which develops and commercializes innovative device-based
solutions in permanent birth control. Earlier this month, Bayer
commenced a cash tender offer to acquire all shares of Conceptus
for $31.00 per share (approx. $ 1.1 billion).
The Conceptus acquisition will add the Essure permanent
(non-surgical) birth control system to Bayer's product portfolio.
We note that Conceptus' Essure procedure was approved in 2002 in
the US and is well accepted in the market. Successful completion
of the acquisition would ensure the presence of short-term,
long-term and permanent contraceptive choices from Bayer's
portfolio for women.
Bayer presently carries a Zacks Rank #3 (Hold). Other stocks
Alexion Pharmaceuticals Inc.
) currently look more attractive. Both stocks carry a Zacks Rank
ALKERMES INC (ALKS): Free Stock Analysis
ALEXION PHARMA (ALXN): Free Stock Analysis
BAYER A G -ADR (BAYRY): Free Stock Analysis
CONCEPTUS INC (CPTS): Free Stock Analysis
To read this article on Zacks.com click here.